Belumosudil mesylate is under clinical development by Kadmon Holdings and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Belumosudil mesylate’s likelihood of approval (LoA) and phase transition for Systemic Sclerosis (Scleroderma) took place on 08 Feb 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Belumosudil mesylate Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Belumosudil mesylate overview

Belumosudil mesylate (Rezurock/ Rholistiq) is an immunosuppressant. It is formulated as film coated tablets and tablets for oral route of administration. Rezurock is indicated for the treatment of adult and pediatric patients 12 years and older with chronic graft-versus-host disease (cGVHD) after failure of at least two prior lines of systemic therapy and who have an inadequate response to corticosteroids. Belumosudil mesylate (KD-025, SLx-2119) is under development for the treatment of idiopathic pulmonary fibrosis, diffuse cutaneous systemic sclerosis and graft versus host disease. It is a small molecule administered through orally and parenteral route. It is a selective inhibitor of Rho kinase 2 (ROCK2). It is developed based on Pharmacomer Technology Platform. It was also under development for the treatment of atherosclerosis, Sjogren’s syndrome, NASH (Nonalcoholic steatohepatitis), inflammatory bowel disease, multiple sclerosis, systemic lupus erythematosus, psoriatic arthritis, systemic sclerosis (scleroderma), psoriasis vulgaris, rheumatoid arthritis and lupus nephritis.

Kadmon Holdings overview

Kadmon Holdings (Kadmon) is an integrated biopharmaceutical company that discovers, develops and markets small molecules and biologics for autoimmune and fibrotic diseases, various types of cancer, and genetic diseases. The company’s pipeline encompasses investigational candidates for the treatment of moderate to severe psoriasis, idiopathic pulmonary fibrosis, and polycystic kidney disease among others. Its pipeline candidates are based on its small molecule and biologics platforms. It also develops in-licensed product candidates and technologies. The company works in partnership with various pharmaceutical and biopharmaceutical companies to advance its pipeline candidates. Kadmon is headquartered in New York, the US.

Quick View Belumosudil mesylate LOA Data

Report Segments
  • Innovator (NME)
Drug Name
  • Belumosudil mesylate
Administration Pathway
  • Oral
  • Parenteral
Therapeutic Areas
  • Cardiovascular
  • Central Nervous System
  • Gastrointestinal
  • Immunology
  • Musculoskeletal Disorders
  • Respiratory
Key Developers
  • Sponsor Company: Kadmon Holdings
  • Originator: Surface Logix
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.